http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Mar 2026 16:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ABBOTT+LABORATORIES+++++++For%3A+Dec+31/26159428.html si-local-file:///var/storage/secattach/20260313/26159428.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ABBOTT+LABORATORIES+++++++For%3A+Dec+31/26159428.html Fri, 13 Mar 2026 16:02:00 -0400 ABT O.00000296 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ABBOTT+LABORATORIES+++++++For%3A+Dec+31/26159428.html si-local-file:///var/storage/secattach/20260313/26159428.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ABBOTT+LABORATORIES+++++++For%3A+Dec+31/26159428.html Fri, 13 Mar 2026 16:02:00 -0400 ABT O.00000296 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ABBOTT+LABORATORIES+++++++For%3A+Apr+24/26159411.html si-local-file:///var/storage/secattach/20260313/26159411.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ABBOTT+LABORATORIES+++++++For%3A+Apr+24/26159411.html Fri, 13 Mar 2026 16:01:00 -0400 ABT O.00000296 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ABBOTT+LABORATORIES+++++++For%3A+Apr+24/26159411.html si-local-file:///var/storage/secattach/20260313/26159411.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ABBOTT+LABORATORIES+++++++For%3A+Apr+24/26159411.html Fri, 13 Mar 2026 16:01:00 -0400 ABT O.00000296 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ABBOTT+LABORATORIES++++++++++++++++++/26159418.html si-local-file:///var/storage/secattach/20260313/26159418.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ABBOTT+LABORATORIES++++++++++++++++++/26159418.html Fri, 13 Mar 2026 16:01:00 -0400 ABT O.00000296 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ABBOTT+LABORATORIES++++++++++++++++++/26159418.html si-local-file:///var/storage/secattach/20260313/26159418.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ABBOTT+LABORATORIES++++++++++++++++++/26159418.html Fri, 13 Mar 2026 16:01:00 -0400 ABT O.00000296 http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+Abbott+Labs+%28ABT%29+on+DD+Medical+Device+Growth+Sustainability/26157343.html <p>UBS analyst Danielle Antalffy reiterated a Buy rating and $158.00 price target on Abbott Labs (NYSE: ABT).</p><p>The analyst commented, "We think ABT's structural heart business could see meaningful upside on the back of a positive CHAMPION readout at the end of this month (presenting at ACC on 3/28), which is underappreciated today. We acknowledge that ABT shares are down 11% YTD and 21% off their 52 week highs following a disappointing Q4 and 2026 guide, largely driven by a revamped pricing strategy in Nutrition, but also see this movement as exacerbated by questions around deceleration in key growth areas within http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+Abbott+Labs+%28ABT%29+on+DD+Medical+Device+Growth+Sustainability/26157343.html Fri, 13 Mar 2026 09:37:52 -0400 ABT http://www.streetinsider.com/Analyst+Comments/Abbott+Labs+%28ABT%29+Reiterated+at+Buy+by+Benchmark+After+FreeDM+Trial+Results/26156351.html <p>Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $145.00 price target on Abbott Labs (NYSE: ABT).</p><p>The analyst commented, "Abbott Labs announced results from the FreeDM trial showing that Type 2 diabetics on basal insulin therapy who used the FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes compared to those using whole blood glucose meters with fingerstick blood samples. The difference between the two groups was statistically significant. Participants were on basal insulin with either an SGLT2 inhibitor or a GLP 1 receptor agonist, indicating meaningful benefit even among people already on advanced glucose-lowering therapies. The http://www.streetinsider.com/Analyst+Comments/Abbott+Labs+%28ABT%29+Reiterated+at+Buy+by+Benchmark+After+FreeDM+Trial+Results/26156351.html Fri, 13 Mar 2026 07:12:27 -0400 ABT http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/Press+Releases/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html <div class="xn-content"> <ul type="disc"><li><location value="LC/gb" idsrc="xmltag.org" >U.K.</location> FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks ^1,2</li><li>Improvements were participant-led, using real-time glucose readings to guide everyday decisions</li><li>Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population³</li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 12, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology http://www.streetinsider.com/PRNewswire/Landmark+study+shows+Libre+technology+helps+people+with+Type+2+diabetes+on+basal+insulin+improve+glucose+management/26149455.html Thu, 12 Mar 2026 08:00:00 -0400 A.17865029 A.37167078 ABT O.00000296 O.00498106 O.19975525 http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html <div class="xn-content"> <ul type="disc"><li><span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span>, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team'</li><li>All participants will receive sports nutrition guidance from <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> experts and take part in on-field development sessions led by Real Madrid coaches</li><li>The 16 selected male and female '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team' members, ages 18–19, will travel to <location value="LC/es" idsrc="xmltag.org" >Spain</location> on an all‑expenses‑paid trip to train at Real Madrid's official facilities</li><li>Learn more and register at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4638474-1&amp;h=2856609210&amp;u=http%3A%2F%2Fwww.abbottdreamteam.com%2F&amp;a=AbbottDreamTeam.com" target="_blank" rel="nofollow">AbbottDreamTeam.com</a></li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 11, 2026</chron></span> http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html Wed, 11 Mar 2026 11:00:00 -0400 A.34563541 ABT O.00000296 O.19939975 http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html <div class="xn-content"> <ul type="disc"><li><span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span>, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team'</li><li>All participants will receive sports nutrition guidance from <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> experts and take part in on-field development sessions led by Real Madrid coaches</li><li>The 16 selected male and female '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team' members, ages 18–19, will travel to <location value="LC/es" idsrc="xmltag.org" >Spain</location> on an all‑expenses‑paid trip to train at Real Madrid's official facilities</li><li>Learn more and register at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4638474-1&amp;h=2856609210&amp;u=http%3A%2F%2Fwww.abbottdreamteam.com%2F&amp;a=AbbottDreamTeam.com" target="_blank" rel="nofollow">AbbottDreamTeam.com</a></li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 11, 2026</chron></span> http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html Wed, 11 Mar 2026 11:00:00 -0400 A.34563541 ABT O.00000296 O.19939975 http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html <div class="xn-content"> <ul type="disc"><li><span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span>, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team'</li><li>All participants will receive sports nutrition guidance from <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> experts and take part in on-field development sessions led by Real Madrid coaches</li><li>The 16 selected male and female '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team' members, ages 18–19, will travel to <location value="LC/es" idsrc="xmltag.org" >Spain</location> on an all‑expenses‑paid trip to train at Real Madrid's official facilities</li><li>Learn more and register at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4638474-1&amp;h=2856609210&amp;u=http%3A%2F%2Fwww.abbottdreamteam.com%2F&amp;a=AbbottDreamTeam.com" target="_blank" rel="nofollow">AbbottDreamTeam.com</a></li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 11, 2026</chron></span> http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html Wed, 11 Mar 2026 11:00:00 -0400 A.34563541 ABT O.00000296 O.19939975 http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html <div class="xn-content"> <ul type="disc"><li><span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span>, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team'</li><li>All participants will receive sports nutrition guidance from <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> experts and take part in on-field development sessions led by Real Madrid coaches</li><li>The 16 selected male and female '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team' members, ages 18–19, will travel to <location value="LC/es" idsrc="xmltag.org" >Spain</location> on an all‑expenses‑paid trip to train at Real Madrid's official facilities</li><li>Learn more and register at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4638474-1&amp;h=2856609210&amp;u=http%3A%2F%2Fwww.abbottdreamteam.com%2F&amp;a=AbbottDreamTeam.com" target="_blank" rel="nofollow">AbbottDreamTeam.com</a></li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 11, 2026</chron></span> http://www.streetinsider.com/Press+Releases/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html Wed, 11 Mar 2026 11:00:00 -0400 A.34563541 ABT O.00000296 O.19939975 http://www.streetinsider.com/PRNewswire/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html <div class="xn-content"> <ul type="disc"><li><span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span>, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team'</li><li>All participants will receive sports nutrition guidance from <span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> experts and take part in on-field development sessions led by Real Madrid coaches</li><li>The 16 selected male and female '<span value="NYSE:ABT" idsrc="xmltag.org">Abbott</span> Dream Team' members, ages 18–19, will travel to <location value="LC/es" idsrc="xmltag.org" >Spain</location> on an all‑expenses‑paid trip to train at Real Madrid's official facilities</li><li>Learn more and register at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4638474-1&amp;h=2856609210&amp;u=http%3A%2F%2Fwww.abbottdreamteam.com%2F&amp;a=AbbottDreamTeam.com" target="_blank" rel="nofollow">AbbottDreamTeam.com</a></li></ul><p><span class="legendSpanClass"><person>ABBOTT PARK</person>, Ill.</span>, <span class="legendSpanClass"><chron>March 11, 2026</chron></span> http://www.streetinsider.com/PRNewswire/Abbott+and+Real+Madrid+launch+nationwide+effort+to+build+the+next+%27Abbott+Dream+Team%27/26144324.html Wed, 11 Mar 2026 11:00:00 -0400 A.34563541 ABT O.00000296 O.19939975